Fecal Constipation, Fecal Incontinence, Multiple Sclerosis, Neurogenic Bowel (Disorder)
Conditions
Brief summary
A randomized, superiority, controlled, interventional, prospective, multicentre, post-market study of TAI with Navina™ Smart versus Standard Bowel Care performed in a population of 92 subjects suffering from Multiple Sclerosis and confirmed Neurogenic Bowel Dysfunction. The study is expected to last for a total of 8 weeks per subject with two scheduled site visits.
Interventions
DEVICENavina Smart
CE-marked NavinaTM Smart including Navina Smart App.
OTHERStandard Bowel Care
Bowel care will be scheduled at least every 2nd day according to a defined study specific standard bowel care protocol. Diet, fluids, abdominal massage, regular physical activity and medications will be used if non-interventional treatment is insufficient.
Sponsors
Wellspect HealthCare
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
For inclusion in the study, subjects must fulfil all of the following criteria: 1. Provision of informed consent. 2. Female or male aged 18 years or above. 3. Established diagnosis of MS according to McDonald criteria. 4. Patients with bowel symptoms post-dating and related to a diagnosis of MS. 5. Patients suffering from NBD symptoms defined by Wexner feacal incontinence score ≥10 and/or Cleveland Clinic constipation score ≥10 confirmed at Baseline. 6. Only TAI treatment naïve patient (not having previously used any particular TAI system). 7. Judged eligible for TAI as per standardized treatment pathway. 8. Able to read, write and understand information given to them regarding the study.
Exclusion criteria
Any of the following is regarded as a criterion for exclusion from the study: 1. Any confirmed or suspected diagnosis of anal or colorectal stenosis, active inflammatory bowel disease, acute diverticulitis, severe diverticulosis, colorectal cancer, ischemic colitis, history of life-threatening autonomic dysreflexia, bleeding disorders, unspecified peri-anal conditions. 2. Untreated rectal impaction. 3. Other significant neurological diseases (defined as all neurological diseases except for minor functional neurological syndromes or non-MS related neuro complications). 4. Opioid consumption ≤24 hours prior enrolment. 5. Previous colorectal surgery (including haemorrhoidectomy and fistulotomy), sphincter injury, perianal sepsis, rectal prolapse. 6. Performed endoscopic polypectomy within 4 weeks prior enrolment. 7. Ongoing, confirmed pregnancy or lactation. 8. Any neuromodulation that can affect the pelvic organ function. 9. Ongoing, symptomatic Urinary Tract Infection (UTI) at enrolment (defined as a positive urine culture of ≥10\^3 CFU/ml of ≥1 bacterial species and presence of symptoms or signs compatible with UTI with no other identified source of infection).\* 10. Current treatment with anticoagulants (exception acetylsalicylic acid or clopidogrel). 11. Current treatment with long-term systemic steroid medication (exception inhalation agents and/or local topical treatment). 12. Current treatment of prokinetics. 13. Involvement in the planning and conduct of the study (applies to both Wellspect HealthCare and site personnel). 14. Previous enrolment in the present study. 15. Simultaneous participation in another clinical study that may interfere with the present study as judged by the investigator. 16. Expected severe non-compliance to protocol as judged by the investigator. 17. Any other condition, as judged by the investigator, which might make follow-up or investigations inappropriate. 18. Any patient that according to the Declaration of Helsinki is unsuitable for enrolment. 19. Agranulocytosis (\<0.5 10\^9 / L) \[Only applicable for Switzerland\]. * If symptoms and signs compatible with UTI is present but no urine culture test has been performed yet, a test should be performed, and the result received prior evaluating if the subject is eligible for study participation. After successful and completed treatment of a UTI, the subject may be rescheduled for Visit 1 in order to re-evaluate study participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in fecal incontinence score. | 8 weeks | Relative change in Wexner fecal incontinence score at 8 weeks relative to Baseline in the TAI arm, compared to the SBC arm. |
| Change in fecal constipation score | 8 weeks. | Relative change in Cleveland Clinic constipation score at 8 weeks relative to Baseline in the TAI arm, compared to the SBC arm. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in NBD symptoms | 4 weeks and 8 weeks | Absolute and relative change in NBD score between Baseline and 4 and 8 weeks in the Navina arm, compared to the SBC arm. |
| Change in bladder specific QoL | 8 weeks | Absolute and relative change in SF-Qualiveen questionnaire between Baseline and 8 weeks in the TAI arm, compared to the SBC arm. |
| Study therapy adherence | 4 weeks and 8 weeks | Number of subjects using Navina Smart or SBC at 4 weeks and 8 weeks treatment, as measured by a single question. |
| Efficacy of TAI with Navina Smart vs. SBC | 4 weeks | Absolute change in Wexner fecal incontinence score at 4 weeks relative to Baseline in the TAI arm, compared to the SBC arm. |
| Navina Smart: Correlation APP/irrigation parameters | Up to 3 weeks | Volume correlation with Anorectal Physiology Parameters (APPs) up to 3 weeks from baseline in subjects who perform the anorectal physiology test, treated with Navina Smart, and using the Navina Smart App. |
| Navina Smart: Correlation anorectal APP/irrigation parameters between responders/non-responders | Up to 3 weeks | Correlation between Anorectal Physiology Parameters (APPs), irrigations parameters (volume/frequency of irrigation and balloon inflation) and outcome of TAI treatment between responders versus non-responders in subjects who perform the anorectal physiology test, treated with Navina Smart, and using the Navina Smart App from baseline to 3 weeks. A responder is defined as an improvement equal to the 25th percentile of the change in Cleveland Clinic Constipation score when using TAI with Navina Smart. |
| Frequency of UTI | 8 weeks | Number of UTIs requiring antibiotic treatment 8 weeks prior study start (Baseline) and at 8 weeks after treatment (Visit 2), as reported by subject. |
| Change in perception of impact of bowel symptoms on QoL | 8 weeks | Relative change of impact on bowel-related QoL between baseline and 8 weeks in the TAI arm, compared to the SBC arm, as measured by a single question. |
Countries
Denmark, France, Italy, Spain, Switzerland, United Kingdom
Contacts
Primary ContactWellspect HealthCare
Outcome results
None listed